Literature DB >> 29428251

Adaptive Boost Target Definition in High-Risk Head and Neck Cancer Based on Multi-imaging Risk Biomarkers.

Feifei Teng1, Madhava Aryal1, Jae Lee1, Choonik Lee1, Xioajin Shen1, Peter G Hawkins1, Michelle Mierzwa2, Avraham Eisbruch1, Yue Cao3.   

Abstract

PURPOSE: Positron emission tomography with 18F-deoxyglucose (FDG), dynamic contrast-enhanced magnetic resonance imaging (MRI), and diffusion-weighted MRI each identify unique risk factors for treatment outcomes in head and neck cancer (HNC). Clinical trials in HNC largely rely on a single imaging modality to define targets for boosting. This study aimed to investigate the spatial correspondence of FDG uptake, perfusion, and the apparent diffusion coefficient (ADC) in HNC and their response to chemoradiation therapy (CRT) and to determine the implications of this overlap or lack thereof for adaptive boosting. METHODS AND MATERIALS: Forty patients with HNC enrolled in a clinical trial underwent FDG positron emission tomography-computed tomography before CRT and underwent dynamic contrast-enhanced and diffusion-weighted MRI scans before and during CRT. The gross tumor volume (GTV) of the primary tumor was contoured on post-gadolinium T1-weighted images. Tumor subvolumes with high FDG uptake, low blood volume (BV), and low ADC were created by using previously established thresholds. Spatial correspondences between subvolumes were analyzed using the Dice coefficient, and those between each pair of image parameters at voxel level were analyzed by Spearman rank correlation coefficients.
RESULTS: Prior to CRT, the median subvolumes of high FDG, low BV, and low ADC relative to the primary GTV were 20%, 21%, and 45%, respectively. Spearman correlation coefficients between BV and ADC varied from -0.47 to 0.22; between BV and FDG, from -0.08 to 0.59; and between ADC and FDG, from -0.68 to 0.25. Dice coefficients between subvolumes of FDG and BV, FDG and ADC, and BV and ADC were 10%, 46%, and 15%, respectively. The union of the 3 parameters was 64% of the GTV. The union of the subvolumes of BV and ADC was 56% of the GTV before CRT but was reduced significantly by 57% after 10 fractions of radiation therapy.
CONCLUSIONS: High FDG uptake, low BV, and low ADC as imaging risk biomarkers of HNC identify largely distinct tumor characteristics. A single imaging modality may not define the boosting target adequately.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29428251      PMCID: PMC6013352          DOI: 10.1016/j.ijrobp.2017.12.269

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  48 in total

1.  Adaptive dose painting by numbers for head-and-neck cancer.

Authors:  Fréderic Duprez; Wilfried De Neve; Werner De Gersem; Marc Coghe; Indira Madani
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-07-17       Impact factor: 7.038

2.  Optimization of tumour control probability in hypoxic tumours by radiation dose redistribution: a modelling study.

Authors:  Aste Søvik; Eirik Malinen; Øyvind S Bruland; Søren M Bentzen; Dag Rune Olsen
Journal:  Phys Med Biol       Date:  2006-12-29       Impact factor: 3.609

3.  Positron emission tomography-guided, focal-dose escalation using intensity-modulated radiotherapy for head and neck cancer.

Authors:  Indira Madani; Wim Duthoy; Cristina Derie; Werner De Gersem; Tom Boterberg; Micky Saerens; Filip Jacobs; Vincent Grégoire; Max Lonneux; Luc Vakaet; Barbara Vanderstraeten; Wouter Bauters; Katrien Bonte; Hubert Thierens; Wilfried De Neve
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-05-01       Impact factor: 7.038

4.  Prognostic significance of 18F-FDG PET parameters and plasma Epstein-Barr virus DNA load in patients with nasopharyngeal carcinoma.

Authors:  Kai-Ping Chang; Ngan-Ming Tsang; Chun-Ta Liao; Cheng-Lung Hsu; Ming-Jui Chung; Chuan-Wei Lo; Sheng-Chieh Chan; Shu-Hang Ng; Hung-Ming Wang; Tzu-Chen Yen
Journal:  J Nucl Med       Date:  2012-01       Impact factor: 10.057

5.  Use of quantitative diffusion-weighted magnetic resonance imaging to predict human papilloma virus status in patients with oropharyngeal squamous cell carcinoma.

Authors:  Mitsuhiko Nakahira; Naoko Saito; Hiroshi Yamaguchi; Kiyomi Kuba; Masashi Sugasawa
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-07-24       Impact factor: 2.503

6.  Prognostic value of 18F-fludeoxyglucose uptake in 287 patients with head and neck squamous cell carcinoma.

Authors:  Jacob H Rasmussen; Ivan R Vogelius; Barbara M Fischer; Jeppe Friborg; Marianne C Aznar; Gitte F Persson; Katrin Håkansson; Claus A Kristensen; Søren M Bentzen; Lena Specht
Journal:  Head Neck       Date:  2014-07-21       Impact factor: 3.147

7.  Diffusion-weighted magnetic resonance imaging for predicting and detecting early response to chemoradiation therapy of squamous cell carcinomas of the head and neck.

Authors:  Sungheon Kim; Laurie Loevner; Harry Quon; Eric Sherman; Gregory Weinstein; Alex Kilger; Harish Poptani
Journal:  Clin Cancer Res       Date:  2009-02-01       Impact factor: 12.531

8.  Diffusion-weighted MR imaging in laryngeal and hypopharyngeal carcinoma: association between apparent diffusion coefficient and histologic findings.

Authors:  Juliette P Driessen; Joana Caldas-Magalhaes; Luuk M Janssen; Frank A Pameijer; Nina Kooij; Chris H J Terhaard; Wilko Grolman; Marielle E P Philippens
Journal:  Radiology       Date:  2014-04-17       Impact factor: 11.105

9.  Patterns of failure in patients receiving definitive and postoperative IMRT for head-and-neck cancer.

Authors:  K S Clifford Chao; Gokhan Ozyigit; Binh N Tran; Mustafa Cengiz; James F Dempsey; Daniel A Low
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-02-01       Impact factor: 7.038

10.  Correlation between pretreatment FDG-PET biological target volume and anatomical location of failure after radiation therapy for head and neck cancers.

Authors:  Daniel E Soto; Marc L Kessler; Morand Piert; Avraham Eisbruch
Journal:  Radiother Oncol       Date:  2008-06-12       Impact factor: 6.280

View more
  5 in total

1.  Early HPV ctDNA Kinetics and Imaging Biomarkers Predict Therapeutic Response in p16+ Oropharyngeal Squamous Cell Carcinoma.

Authors:  Yue Cao; Catherine T Haring; Michelle Mierzwa; J Chad Brenner; Collin Brummel; Chandan Bhambhani; Madhava Aryal; Choonik Lee; Molly Heft Neal; Apurva Bhangale; Wenjin Gu; Keith Casper; Kelly Malloy; Yilun Sun; Andrew Shuman; Mark E Prince; Matthew E Spector; Steven Chinn; Jennifer Shah; Caitlin Schonewolf; Jonathan B McHugh; Ryan E Mills; Muneesh Tewari; Francis P Worden; Paul L Swiecicki
Journal:  Clin Cancer Res       Date:  2021-10-26       Impact factor: 13.801

2.  Real-Time Quantitative Assessment of Accuracy and Precision of Blood Volume Derived from DCE-MRI in Individual Patients During a Clinical Trial.

Authors:  Madhava P Aryal; Choonik Lee; Peter G Hawkins; Christina Chapman; Avraham Eisbruch; Michelle Mierzwa; Yue Cao
Journal:  Tomography       Date:  2019-03

3.  Prediction of the effects of radiation therapy in esophageal cancer using diffusion and perfusion MRI.

Authors:  Peiliang Wang; Xin Wang; Liang Xu; Jinming Yu; Feifei Teng
Journal:  Cancer Sci       Date:  2021-10-20       Impact factor: 6.716

4.  Predictive Values of MRI and PET Derived Quantitative Parameters for Patterns of Failure in Both p16+ and p16- High Risk Head and Neck Cancer.

Authors:  Yue Cao; Madhava Aryal; Pin Li; Choonik Lee; Matthew Schipper; Peter G Hawkins; Christina Chapman; Dawn Owen; Aleksandar F Dragovic; Paul Swiecicki; Keith Casper; Francis Worden; Theodore S Lawrence; Avraham Eisbruch; Michelle Mierzwa
Journal:  Front Oncol       Date:  2019-11-14       Impact factor: 6.244

5.  Correlation between histogram-based DCE-MRI parameters and 18F-FDG PET values in oropharyngeal squamous cell carcinoma: Evaluation in primary tumors and metastatic nodes.

Authors:  Antonello Vidiri; Emma Gangemi; Emanuela Ruberto; Rosella Pasqualoni; Rosa Sciuto; Giuseppe Sanguineti; Alessia Farneti; Maria Benevolo; Francesca Rollo; Francesca Sperati; Filomena Spasiano; Raul Pellini; Simona Marzi
Journal:  PLoS One       Date:  2020-03-02       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.